Sign In
Buy MCRB
$7.17
-0.160 (-2.18%)
At Close: Jun 03, 2026
Seres Therapeutics to Present at the 31st Annual Oppenheimer Healthcare Conference
07:00am, Friday, 12'th Mar 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc., (Nasdaq: MCRB), a leading microbiome therapeutics company, announced that managment will present a corporate overview at the 31st Annual Op
Seres Therapeutics, Inc. (MCRB) CEO Eric Shaff on Q4 2020 Results - Earnings Call Transcript
11:06am, Tuesday, 02'nd Mar 2021
Seres Therapeutics, Inc. (MCRB) CEO Eric Shaff on Q4 2020 Results - Earnings Call Transcript
Seres Therapeutics (MCRB) Reports Q4 Loss, Tops Revenue Estimates
09:05am, Tuesday, 02'nd Mar 2021
Seres Therapeutics (MCRB) delivered earnings and revenue surprises of 30.77% and 99.98%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Seres Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Updates
07:00am, Tuesday, 02'nd Mar 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc., (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported fourth quarter and full year 2020 financial results and provided
Seres Therapeutics to Participate in Upcoming Virtual Investor Conferences
08:00am, Friday, 26'th Feb 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc., (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will participate in two upcoming investor confer
Earnings Preview: Seres Therapeutics (MCRB) Q4 Earnings Expected to Decline
01:42pm, Monday, 22'nd Feb 2021
Seres Therapeutics (MCRB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
4D Pharma: Impressive Immuno-Oncology Data
06:00pm, Tuesday, 16'th Feb 2021
4D Pharma: Impressive Immuno-Oncology Data
Seres Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference
07:00am, Wednesday, 06'th Jan 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced that it will present a corporate overview at the 39th Annual J.P. Morgan Healthcare Conference on Thursday, J
5 Medical Outperformers That Might Lose Steam in 2021
10:32am, Tuesday, 22'nd Dec 2020
Here we discuss some biotech stocks, which are up this year so far but might not be good additions to your portfolio.
These Were the 10 Best Healthcare Stocks of 2020
06:35am, Tuesday, 15'th Dec 2020
The highest performers of the year are biotechs fighting COVID-19 and cancer. Are they still buys for 2021?
These 5 Mid-Cap Healthcare Stocks Had the Best Gains in 2020
06:45am, Friday, 11'th Dec 2020
Investors favored coronavirus vaccine work, late-stage trial victories, and genetic sequencing.
Seres Therapeutics: Microbiomics Back In The Game
08:39am, Friday, 13'th Nov 2020
Late August spike means share price moves from below $5 to more than $30. Capital raising and Nestle agreement raised $264 million.
Seres Therapeutics' SER-109 Has Accelerated Growth Potential
06:42pm, Thursday, 12'th Nov 2020
Seres has seen +863% upside YTD on the back of positive top-line data in their phase 3 SER-109 study, which helps prove their microbiome hypotheses. Management have strengthened the cash position and
Seres Therapeutics, Inc. (MCRB) CEO Eric Shaff on Q3 2020 Results - Earnings Call Transcript
01:55pm, Monday, 09'th Nov 2020
Seres Therapeutics, Inc. (MCRB) CEO Eric Shaff on Q3 2020 Results - Earnings Call Transcript
Seres Therapeutics Announces Initiation of Phase 1b Trial of SER-301 for the Treatment of Ulcerative Colitis
07:00am, Friday, 06'th Nov 2020
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced that it has dosed the first patient in its Phase 1b trial evaluating SER-301 for the treatment of active mild
